Trials / Completed
CompletedNCT04843540
Drug-drug Interaction Study of CTP-543 and Rifampin in Healthy Adult Subjects
A Phase 1 Open-Label Study to Assess the Effect of a Strong CYP3A4 Inducer, Rifampin, on the Single Dose Pharmacokinetic Profile of CTP-543 in Healthy Adult Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 22 (actual)
- Sponsor
- Concert Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Accepted
Summary
This is a Phase 1 open-label study of the effect of rifampin on the pharmacokinetics of CTP-543 in healthy subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CTP-543 | Rifampin as oral capsule |
Timeline
- Start date
- 2021-05-19
- Primary completion
- 2021-06-24
- Completion
- 2021-07-02
- First posted
- 2021-04-13
- Last updated
- 2021-07-20
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04843540. Inclusion in this directory is not an endorsement.